Investor Letter to Danaher Commending Test Price Reduction

ICCR Comment/Sign On Letters

A key product in the effort to end TB is diagnostic testing. More than 1 in 3 people with TB go undiagnosed, and part of the reason why is lack of access to and affordability of testing. Last September, Cepheid, a molecular diagnostic company and subsidiary of Danaher Corporation, announced a 20% price reduction of its Xpert test cartridges used to diagnose TB, and will sell them at cost. Critically, Cepheid said it will allow a third-party organization to validate their costs annually to confirm the at-cost price.

On March 19, 2024, ICCR members and socially responsible investment firms wrote to Danaher, commending the company for Cepheid’s Xpert test price reduction, and for the annual independent validation of the cost of the product. The letter asks that Danaher set up a committee of stakeholders to give advice on and be informed of the process and methodology used for the audit.

Julie Wokaty

Read our letter

ICCR Statement in Response to ExxonMobil Lawsuit to Block Shareholder Climate-Related Proposal

On January 21, ExxonMobil ($XOM) filed suit in Texas against two shareholders in an attempt to block a shareholder proposal urging the company to accelerate the reduction of greenhouse gas (GHG) emissions and to disclose new plans and timetables for these reductions. ICCR released the following statement.

Investor Statement of Support for a Living Wage for U.S. Workers

On November 15, 2023, the undersigned investors, representing $4.5 trillion in assets under management and advisement, call on U.S. companies to take steps towards the payment of a living wage to direct and contract workers, in line with international human rights standards. Long-term investments in the workforce are good for business, helping companies attract and […]

Amicus Curiae Brief Submitted by ICCR in Support of the SEC in SEC v NCPPR Case

ICCR submitted this amicus curiae brief on September 21, 2023.

Letter to CEO Members of the Business Roundtable (BRT) Regarding their Political Spending Activities

On August 10, 2023, members of the Interfaith Center on Corporate Responsibility (ICCR) announced they had sent letters to members of the Business Roundtable urging them to align political spending with their stated core values, to mitigate both reputational risks to the company, and broader risks to democracy.

Food equity: The intersection of health and racial justice

In a letter sent to 21 companies including Coca-Cola ($KO), Kraft ($KHC), Unilever ($UL), McDonald’s ($MCD), and Amazon ($AMZN) among other iconic brands, the investors pointed to the COVID-19 crisis and how it has exposed inequitable systems that contribute to the economic and health struggles of Black, Latinx and Indigenous communities in the U.S. The investors argue that the way food is developed and marketed to communities […]

Joint Investor Letter to Nike on Outstanding Wage Payments

In September of 2023, ICCR coordinated a group of investors in sending a letter to Nike to express significant concern over non-payment issues at two Nike suppliers.

Investor Statement Regarding Pharma Medicare Lawsuit

On August 31, 2023 investors released a statement voicing deep concern about lawsuits brought by pharma companies and trade groups to block the U.S. government’s ability to negotiate fair drug prices for Medicare beneficiaries. The statement, which was endorsed by more than 30 institutional investors, is being sent to Astellas Pharma, Inc. ($ALPMY), AstraZeneca ($AZN), Bristol-Myers Squibb Company ($BMS), […]

ICCR Comment Letter to ISSB on Systemic Risk and Impact Materiality

ICCR letter to Congress on the reauthorization of the Farm Bill

On June 1, 2023 ICCR submitted the following letter to members of Congress urging them to support legislation that builds healthy, equitable, and sustainable food systems.

Investor Letter to Danaher Commending Test Price Reduction

More ICCR Comment/Sign On Letters